Pediatric Blood & Cancer最新文献

{"title":"Synchronous Mediastinal Germ Cell Tumor with Sarcomatous Transformation and Acute Myeloid Leukemia","authors":"Elysia Cohen, Olayinka Okeleji, David McCall, Miriam Garcia, Cesar Nunez, Branko Cuglievan, Cynthia Herzog, Shehla Razvi, Priti Tewari, Harrison Douglas, Amber Gibson","doi":"10.1002/pbc.32092","DOIUrl":"10.1002/pbc.32092","url":null,"abstract":"","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 12","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145213303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two Surveys, 16 Years Apart: Comparing Traditional and Complementary Medicine Use by Children With Cancer in Jordan","authors":"Murad Sawalha,&nbsp;Anwar Alnaasan,&nbsp;Anas Alsharawneh,&nbsp;Ahmed Farrag,&nbsp;Mohammad R. Alqudimat","doi":"10.1002/pbc.32096","DOIUrl":"10.1002/pbc.32096","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Traditional and complementary medicine (T&amp;CM) is commonly used by children with cancer alongside conventional treatments. However, data on its use in Jordan remain limited. This study aimed to assess the current prevalence, types, motivations, and disclosure rates of T&amp;CM use in Jordan, and to compare these findings with those from the original 2008 study conducted in the same setting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cross-sectional study was conducted in the pediatric oncology department at King Hussein Cancer Center between November 2023 and May 2024. A brief proxy-report T&amp;CM questionnaire with evidence of validity and reliability was used.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 85 patients participated (response rate = 85%). Overall, 29.4% reported T&amp;CM use, primarily for perceived safety (52%), managing cancer-related symptoms (44%), and potential therapeutic benefit (40%). Nutritional (68%) and psychological (24%) approaches were the most used modalities. Disclosure of T&amp;CM use to healthcare providers was reported by 75% of users. Reasons for non-use included a lack of recommendation by healthcare providers and limited awareness. A statistically significant association was found between T&amp;CM use and current therapy stage, with higher use among patients in active treatment. No other demographic or clinical variables were significantly associated with T&amp;CM use.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Compared to earlier findings, this study shows a lower prevalence of T&amp;CM use and a higher disclosure rate, suggesting improved communication and awareness. Parents used T&amp;CM to complement conventional care rather than as an alternative. These findings underscore the importance of integrating discussions about T&amp;CM into pediatric oncology care to support safe and informed use.</p>\u0000 </section>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 12","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemo-Immunotherapy Rescue for High-Risk Neuroblastoma Patients With Progressive Disease Before High-Dose Chemotherapy: Real-World Data From the SACHA-France Study","authors":"Claudia Pasqualini,&nbsp;Stéphanie Proust,&nbsp;Gudrun Schleiermacher,&nbsp;Marion Gambart,&nbsp;Sarah Jannier,&nbsp;Arnaud Petit,&nbsp;Chrystelle Dupraz,&nbsp;Estelle Thebaud,&nbsp;Yves Reguerre,&nbsp;Lee Aymar Ndounga-Diakou,&nbsp;Salim Laghouat,&nbsp;Anne Sophie Defachelles,&nbsp;Pablo Berlanga","doi":"10.1002/pbc.32080","DOIUrl":"10.1002/pbc.32080","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Patients with high-risk neuroblastoma (HR-NBL) who experience disease progression (PD) during first-line treatment prior to high-dose chemotherapy (HDC) represent a rare and understudied subgroup, for whom treatment strategies are poorly defined and prognosis appears to be extremely poor.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>We report real-world data on the off-label use of chemo-immunotherapy for HR-NBL patients with PD before HDC. The primary endpoint of our analysis is the best response during the chemo-immunotherapy treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The SACHA-France registry prospectively documents safety and efficacy data on compassionate/off-label treatments for patients of ≤25 years old (NCT04477681).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Between January 2020 and September 2024, 13 patients with HR-NBL received chemo-immunotherapy due to PD before HDC, and were included in SACHA-France. They had a median age of 3.4 years (1.3–8.0). Six patients had NMYC-amplified disease. Five PD occurred during/end-of-induction chemotherapy, and eight during temozolomide-based chemotherapy after initial insufficient metastatic response or toxicity. All but one had metastatic progression. The chemo-immunotherapy consisted of topotecan–cyclophosphamide (<i>n</i> = 9) or temozolomide–irinotecan (<i>n</i> = 4), combined with dinutuximab beta (dB) for a maximum of six cycles. Objective responses (ORs) were seen in five of 13 patients (38%)—four partial responses (PR) and one complete response (CR). Three out of the five patients with PD during/end of induction had PR, including two with NMYC-amplified tumors. Overall, six patients underwent tandem HDC, with two remaining progression-free after 1.7 and 2.1 years, and one remaining disease-free at 3.4 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Chemo-immunotherapy can benefit HR-NBL patients with PD before HDC, including those with progression during/at the end of the induction chemotherapy and NMYC amplification. These findings support its early inclusion in HR-NBL trials.</p>\u0000 </section>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 12","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.32080","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Food Insecurity With Disease-Related Complications and Healthcare Utilization for Patients With Sickle Cell Disease.","authors":"Sharjeel Syed, Andrew Palmer, Austin Wesevich, Kristen Wroblewski, Gabrielle Lapping-Carr, Radhika Peddinti, Wendy S Darlington","doi":"10.1002/pbc.32100","DOIUrl":"https://doi.org/10.1002/pbc.32100","url":null,"abstract":"<p><strong>Background: </strong>Food insecurity is one of several household material hardships (HMH) recognized for their impact on disease severity and healthcare utilization in patients with chronic disease. Sickle cell disease (SCD) is a chronic disease, disproportionately affecting patients of lower socioeconomic status, that results in high rates of disease-related complications and high healthcare utilization. This study examines the relationship between food insecurity and SCD-related complications and healthcare utilization.</p><p><strong>Methods: </strong>Patients (ages 2-24 years) and/or their parents were surveyed to assess food insecurity status during routine SCD clinic visits from July 2015 to July 2019. Food insecurity status was assessed using the United States Department of Agriculture (USDA) Food Security Short Form (six-item), with a lookback period of 12 months. Sociodemographic characteristics, disease-related complications, and healthcare utilization were abstracted from electronic health records.</p><p><strong>Results: </strong>Overall, 22% (n = 25) of participant households were food insecure. Food insecurity was associated with significantly higher annual rates of acute chest syndrome (aOR = 3.12, 95% CI: 1.27-7.67), prevalence of cholecystectomy (aOR = 6.29, 95% CI: 1.66-23.80), and a higher number of hospitalizations (aOR = 2.40, 95% CI: 1.04-5.52).</p><p><strong>Conclusions: </strong>The rates of food insecurity among sampled households of pediatric and young adult patients with SCD were much higher than national (13.4%) and local county rates (13%). Food insecurity was independently associated with more disease-related complications and higher healthcare utilization even after adjusting for age, sex, and sickle cell type. These results suggest food insecurity may be a modifiable contributor impacting morbidity in patients with SCD and should prompt further study into these relationships.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e32100"},"PeriodicalIF":2.3,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145225702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging the Gap in Pediatric Relapsed Acute Lymphoblastic Leukemia Treatment: Insights and Outcomes From the ALL-IC REL 2016 Guidelines","authors":"Marko Kavcic,&nbsp;Dániel J. Erdélyi,&nbsp;Volkan Hazar,&nbsp;Mirella Ampatzidou,&nbsp;Boryana Avramova,&nbsp;Anca Colita,&nbsp;Monica Makiya,&nbsp;Sophia Polychronopoulou,&nbsp;Bence Hőbör,&nbsp;Tomaz Prelog,&nbsp;Andrea Reyes,&nbsp;Juan Tordecilla,&nbsp;Koray Yalçin,&nbsp;Arend von Stackelberg,&nbsp;Janez Jazbec","doi":"10.1002/pbc.32063","DOIUrl":"10.1002/pbc.32063","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The Acute Lymphoblastic Leukemia InterContinental (ALL-IC) Study Group exemplifies the potential of broad international collaboration. Patient outcomes have improved by standardizing therapeutic options and employing flow cytometry-based minimal residual disease (MRD) for treatment stratification. Nevertheless, relapse occurs in 10%–20% of cases, with survival rates falling short of benchmarks set by top-tier published studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>We aimed to unify treatment guidelines for children with first relapse of ALL across the ALL-IC network, analyze post-relapse outcomes, and report findings from an observational registry.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients were stratified as standard-risk (SR) or high-risk (HR) based on relapse features and genetics. HR criteria included T-cell immunophenotype, very early or early isolated bone marrow relapse, and relapse post-stem cell transplant (SCT). SR was assigned to all others. SCT was indicated in the whole HR group and in SR patients with poor responses (MRD ≥ 0.1% on Day 29).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 370 patients (mean age 9 years; 33.2% female) diagnosed with first relapse between 2017 and 2021, 90.5% had received ALL-IC-Berlin-Frankfurt-Münster (BFM) 2009 treatment initially. Upon relapse, 46.8% were classified as SR and 53.2% as HR. Complete remission rates post-induction were 84% (SR) and 56% (HR). MRD &lt; 0.1% was achieved by 53% (SR) and 29% (HR). Five-year overall survival was 50.5% (74% SR, 32% HR). HR outcomes were hindered by disease progression, treatment toxicity, and posttransplant complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This inaugural ALL-IC REL Consortium report demonstrates promising SR outcomes, akin to the International Study for the Treatment of Childhood Relapsed ALL (IntReALL) findings, but highlights poor HR outcomes with standard chemotherapy. Novel therapeutic strategies are urgently needed in upcoming ALL-IC-BFM REL protocols.</p>\u0000 </section>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 12","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.32063","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145213289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seroreversion of Human Papilloma Virus Antibodies in a Childhood Solid Tumor Survivor Following Three-Dose Vaccination","authors":"Yali Han,&nbsp;Qing Cao,&nbsp;Melissa M. Hudson,&nbsp;Jiaoyang Cai","doi":"10.1002/pbc.32095","DOIUrl":"10.1002/pbc.32095","url":null,"abstract":"","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 12","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145213368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond the Diagnosis: A Child, a Mother, and Cancer in Eastern Congo","authors":"Criss Koba Mjumbe,&nbsp;Christian Tague,&nbsp;Freddy Ahadi Ndiwemo,&nbsp;John Isiko","doi":"10.1002/pbc.32091","DOIUrl":"10.1002/pbc.32091","url":null,"abstract":"&lt;p&gt;RAK is 4 years old. He does not understand what is happening to his body. His belly has grown swollen. His bones ache. His eyes protrude unnaturally, dark rings making his small face look older than his age. He no longer plays with the other children in the camp. He cries often from pain, from fear, and from exhaustion.&lt;/p&gt;&lt;p&gt;It began slowly, like many childhood illnesses: a fever and fatigue. Then, the signs worsened with enlarged lymph nodes, bone tenderness, and distended abdomen. We suspected a malignancy. Tests confirmed neuroblastoma, likely stage M (formerly stage IV), not stage II as initially thought. A disease treatable in high-resource settings, but here, the chances are faint. RAK was born in a place where illness rarely leads to possibility.&lt;/p&gt;&lt;p&gt;His mother, NYK, tells me she did not want to love him at first; not because he was not beautiful, which he was, but because of how he came into the world. He is a child of war, of violence, and of a night NYK would erase if she could. Four years ago, she lived with her husband and five children in Masisi territory, North Kivu Province, in the Democratic Republic of Congo (Figure 1), a fertile region known for its cattle and milk. Life was hard, but stable. Then, came the M23, an armed group that has terrorized eastern Congo for decades [&lt;span&gt;1, 2&lt;/span&gt;]. That night, they entered her village and killed her husband before her eyes. Then, one of the men raped her. She was 31 years old.&lt;/p&gt;&lt;p&gt;She fled with her children to Goma. Weeks later, she learned she was pregnant. At first, she thought of ending the pregnancy. But something perhaps faith, perhaps fatigue, led her to carry it to term. She gave birth in the refugee camp. She named the boy RAK. She tried to separate him from the trauma of his conception. She told herself that he was innocent. Yet, every time she looked at him, she remembered her husband's death and that man's face. And still, she kept him close.&lt;/p&gt;&lt;p&gt;Now, 4 years later, this child born of suffering is the one who needs her most. He is fragile and sick, and she is broken. Her body survived the violence; her spirit barely. Her heart bleeds still, now even more. I remember the first time I saw them. NYK sat on a plastic chair, RAK asleep in her lap. She did not speak for several minutes. When she finally did, her voice trembled. “I think god is testing me,” she whispered. “I have nothing left. Why is He taking my child too?”&lt;/p&gt;&lt;p&gt;There is no easy answer. In the camp, cancer is not only a disease but also a sentence. Access to chemotherapy is extremely limited. Pain control is often inadequate; opioids are scarce. Palliative care is minimal. Every diagnosis feels like a betrayal. We do what we can to relieve pain, offer emotional support, and sometimes arrange referrals to distant centers. But often, it is not enough. RAK is still fighting; so is his mother and so are we. Yet it feels like standing in the tide, with waves too strong to hold back. This story is not only a","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 12","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.32091","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145213309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric Intravenous Iron Therapy: Evaluating the Safety and Efficacy of Iron Isomaltoside and Low-Molecular-Weight Dextran","authors":"Ernesta Dragūnė,&nbsp;Agnė Morkūnaitė,&nbsp;Gaudas Benediktas Trakymas,&nbsp;Ramunė Vaišnorė,&nbsp;Sonata Šaulytė Trakymienė","doi":"10.1002/pbc.32093","DOIUrl":"10.1002/pbc.32093","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Iron deficiency (ID) and iron deficiency anemia (IDA) are prevalent among children and adolescents, affecting growth and development. Although oral iron is the first-line treatment, intravenous (IV) iron is required in cases of poor tolerance or inadequate response. While some IV formulations are used in pediatric clinical practice, no published data on the safety and efficacy of iron isomaltoside (IIM) in the pediatric population exist, while data on low-molecular-weight dextran (LMWD) remain limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Procedure</h3>\u0000 \u0000 <p>Our retrospective cohort study at Vilnius University Hospital Santaros Klinikos (2021–2023) included pediatric patients (&lt;18 years) with ID/IDA receiving IIM or LMWD. Hematological response assessment was based on reticulocyte hemoglobin equivalent (Ret-He) and reticulocyte percentage at 3–7 days (early response), and red blood cell count, hemoglobin (HGB), mean corpuscular volume, serum ferritin, and transferrin saturation at 4–6 weeks (late response).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventy-two patients (IIM: 50, LMWD: 22; 135 infusions), 68% female, with a median age of 13.5 years, were included in the study. Mean HGB increase was 32.4 g/L (IIM) versus 33.1 g/L (LMWD) (<i>p</i> = 0.9). Median ferritin increase was 71.4 µg/L (IIM) versus 117.8 µg/L (LMWD) (<i>p</i> = 0.3). Ret-He improved significantly (<i>p</i> &lt; 0.05). Mild AEs occurred in 5.6%, with similar AE rates in both groups (IIM: 6.0%, LMWD: 4.5%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our findings suggest that IIM and LMWD are effective and safe IV iron therapies for pediatric ID/IDA. Given the lack of data on the safety and efficacy of IIM in the pediatric population, our findings provide valuable preliminary evidence.</p>\u0000 </section>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 12","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145200482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retinoblastoma Research in Africa: A Scoping Review","authors":"Sung Park,&nbsp;Yaw A. Essuman,&nbsp;Sadik T. Sherief,&nbsp;Sameh E. Soliman,&nbsp;Vera A. Essuman,&nbsp;Helen Dimaras","doi":"10.1002/pbc.32074","DOIUrl":"10.1002/pbc.32074","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Achieving equity in childhood cancer represents a global challenge. In Africa, where retinoblastoma has high mortality and morbidity, strengthening research capacity is crucial in developing clinical guidelines from local evidence. This review identified the scope of retinoblastoma research conducted in Africa.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <p>A systematic search identified English-language studies on retinoblastoma in Africa, published between January 1, 2003 and May 15, 2025. Studies were excluded if retinoblastoma was not the primary focus or if Africa was not the main study location. Data collected included journal information, author affiliations, study type, country, purpose, and results. Quantitative findings were summarized with descriptive statistics, while qualitative findings were narratively synthesized.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <p>Of the 1546 citations retrieved, 89 met the inclusion criteria. Single-country studies (<i>n</i> = 85) represented 20 of 54 (37%) African countries, while four multi-country studies increased representation to 43 countries (80%). Most studies were clinical observational (55/89, 62%). Of the 89 studies, 49 (55%) were authored solely by researchers in Africa, but studies which included foreign authors tended to be published in journals with higher journal impact factors (p&lt;0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <p>The growth of retinoblastoma research in Africa reflects both expanding local research capacity and increased international collaboration. However, limited experimental research and basic science studies point to opportunities to strengthen the local evidence base needed to inform clinical guidelines for improving retinoblastoma outcomes in Africa.</p>\u0000 </section>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 12","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/pbc.32074","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurological, Neuropsychological, and Social Outcomes in Pediatric Patients Diagnosed With Cerebellar Mutism Syndrome: A Systematic Review","authors":"Margaret H. Hughes,&nbsp;Joseph Giuseppe R. Paturzo,&nbsp;Callie M. Fernandez,&nbsp;Kareena S. Garg,&nbsp;Jincy Rajan,&nbsp;Suditi Rahematpura,&nbsp;John R. DiBello,&nbsp;Umayr R. Shaikh,&nbsp;Jordan E. Wrigley,&nbsp;Nicholas S. Philips,&nbsp;Darcy Raches,&nbsp;Melissa M. Hudson,&nbsp;Supriya Sarvode","doi":"10.1002/pbc.32072","DOIUrl":"10.1002/pbc.32072","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cerebellar mutism syndrome (CMS) is a postsurgical complication following posterior fossa tumor resection. This review explores long-term neurological, neuropsychological, and social outcomes of children with CMS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A search was performed across multiple databases, focusing on terms related to neoplasms, postoperative complications, and mutism. Selected studies included individuals less than 18 years of age who developed CMS following posterior fossa tumor removal, and developed at least one neurological, neuropsychological, or social outcome.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 2514 publications, 34 studies were included, describing 631 patients aged 1–25.7 years (median = 12 patients; range: 5–107 patients). The prevalence of CMS ranged from 3.7% to 63%, with a median follow-up of 26.5 months (ranging from 2 months to 14.2 years). Ataxia was the most common neurologic outcome reported in 17 studies. Five of nine studies assessing cognitive outcomes noted significantly lower full-scale intelligence quotient/general intellectual ability scores among CMS patients. Emotional changes were observed in 40%–100% of participants across 23 studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>CMS survivors face ongoing neurological, neuropsychological, and behavioral challenges, impacting their quality of life and highlighting the need for advancements in surgical techniques and rehabilitation interventions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"72 12","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}